Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Best buffet on the strip! Make him pay. As a holder who should have more than 5% by now he can afford it :D
If you believe he hasn't sold a single share he would have more than Boyd right now.
Everyfriday is has happy hour. Plus impact could via stocktwits and other means if he was truly genuine. If you believe he's sitting outside IPCI's parking lot counting cars I got a bridge to sell you.
I'm still waiting to find out how he knew Purdue's cars were there during the last run up.
Mind blown
I'd come. But then that would mean you would have to show your face. I think someone was still waiting for you to give him your number you promised.
Would be nice if they sold something off for some immediate capital with the rights for some future revenue from it. Especially if its just going ot sit on a shelf for the next bit
Doog why did you get removed as moderator?
Sorry you are correct. Misread a pr from cerecor
Well someone took a big ownership stake in the company. And he's also ceo of another pharma https://www.cerecor.com let the speculation begin.
http://www.conferencecalltranscripts.org/13G/summary2/?id=4240965
Well the pumpers are back on stocktwits begging for people to buy. So I'm betting another wave of shorting is coming.
I emailed the placement agent to see if I can get copies of the documents. I don't know if it would name the party/parties. We'll see if they respond
Doog, maybe we should visit the facility and speak to them in person.
I think you're right blue
I have a feeling its longer than that Doug. I get ipci learnt from the Teva deal. Why don't you ask the cfo about the expiry dates. He's been pretty forthcoming with me.
E petitions are worthless. What one should do is draft a letter and sign it with the # of shares they own. Then mail it in. If one does up the draft then everyone can just print the generic letter and mail it in on their own.
The cat 3 HAP studies could take upwards of 6 months max maybe?. The cash on hand from this financing plus the increasing revenues should be sufficient till at least then. The raising of capital at this juncture like indicates that they are going forward with those studies now If I had to guess. Its probably enough to get the studies going and a little extra until seroquel revenues pick up. If one is thinking of bailing I'd wait till at least then if I was in the red. (Which I am). Hopefully those studies are done by q1 next year and they can give some positive results with the earnings report. Hell if they said they were already going in the next one it would be nice. But given how hush hush they are I'd be surprised if there was anything that gives forward guidance or insight into the operations.
I've spoken to him via email.
The key question that you should all ask yourselves is "Who is the direct offering to?" This will give you all the confidence to average down and buy more if you can or just wait for them to initiate their play. GLTA
Ah yes.... Standard cryptic impact acting as if he knows. Did they tell you while you were there counting cars and dropping off a bottle of Champagne?
If you believe a word impact says I got realestate on on the moon to sell you.
I agree Doug. That site is pure BS. ONE CAN EASILY see the same idiots on stocktwits being the same ones running that site. It would not take much to connect the dots. It blows my mind that it hasen't been done.
I contacted the board and requested odidi be removed
$3.0 buy order on tsx and he can have all mine at this point
Nevermind how in the earnings they say d cash till Dec and intended to bridge gap with atm. Then do a offering the next day.
Contact the board and demand his removal. Time for us to get active here.
Well that was the most useless post of all time.
Under the terms of the 10-year agreement, we received a non-refundable upfront payment of $3 million in October 2016. In addition, the agreement also provides for a long-term profit sharing arrangement with respect to these licensed products (which includes up to $11 million in cost recovery payments that are payable on future sales of licensed product).
Wonder if they maybe have to hit a milestone for the cost recovery payments
In what state? Maybe a road trip to sit in if it's a public hearing lol.
https://blogs.fda.gov/fdavoice/index.php/2017/09/fda-takes-important-steps-to-stem-the-tide-of-opioid-misuse-and-abuse/
Seems like it has to do mostly with education of dr's prescribing.
I'm sure it's been done and was done a while ago. All Im saying is we really don't know what date the application was fully completed and up to snuff.
Yeah I guess all those motion and prelim dates that were posted earlier regarding Purdue will be represented by nothingness. No one from ipci will be there either when they try to get the class action approved. Silly me. Best defence is to wait for the lawsuit to be approved first before trying to stop it from getting to that stage.
Good.
While eating dinner tonight ask them about all the expenses and fees leading up to a trial.
I don't doubt it. I'm sure MNK looked at everything. But to assume everything went through easy peasy after what we saw at adcom would be wishful thinking. They could've have several problems prior to partnering we don't know. Matter of fact, Angelofoca posted in #30168 that they had to redo bioequivalancy on pristiq in 2013.
Really? Have you ever hired a lawyer before? Those vampires (no offense samasa) charge for every piece of paper that goes through their fingers.
Prelims, motions, discoveries, all that stuff happens before it even reaches a trial and cost a fortune.
They were filed long before signing the deal. There could be been problems prior to inking the deal. Not saying there was, but given how in prepared they were for adcom it's a possibility.
All this bickering back and forth could be cleared up if IPCI got their bloody communication department sorted out. Maybe a conference call or two. I emailed them a week ago now seeking clarity on whether the shelf was still in effect and still no response.
Normally its me glossing over things like that when on nights lol
I thought when saying TSX it would imply Canadian.
Wow...
I'm just happy to wake up and see my sell order for shares I bought at 1.18 on tsx sold at 1.31
Surprised we're up and not down 15%.
Will add again later this week to bring my cost down some more...
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista(TM) NDA
FDA Response Provides Path toward Commercialization of Rexista™
TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, today provided an update on its RexistaTM, henceforth referred to as Oxycodone Hydrochloride Extended-Release Tablets ("Oxycodone ER"), program.
The Company has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") for its Oxycodone ER New Drug Application ("NDA"). In its CRL, the FDA provided certain recommendations and requests for information, including that Intellipharmaceutics complete the relevant Category 2 and Category 3 studies to assess the abuse-deterrent properties of Oxycodone ER by the oral and nasal routes of administration. The FDA also requested additional information related to the inclusion of the blue dye in the Oxycodone ER formulation, which is intended to deter abuse. The FDA has determined that it cannot approve the application in its present form.
"We are very encouraged by the FDA's response as it clarifies our path forward for Oxycodone ER," said, Dr. Isa Odidi, CEO of Intellipharmaceutics. "We had already planned the additional Category 2 and Category 3 studies the FDA has requested and we do not expect they will impact our anticipated commercialization timeline for Oxycodone ER."
Intellipharmaceutics has been given one year to respond to the CRL, and can request additional time if necessary. The FDA has also requested that Intellipharmaceutics submit an alternate proposed proprietary name for Oxycodone ER.
Dr. Odidi concluded, "We will continue to work closely with the FDA to provide them with the additional information they requested, including data supporting the label claims related to Oxycodone ER's abuse-deterrent properties. We believe our Oxycodone ER product can play an important preventative role in the midst of a serious opioid abuse crisis particularly impacting North America. The Company will be providing regular updates as we execute on our Oxycodone ER NDA resubmission plan."
There can be no assurance that Intellipharmaceutics will not be required to conduct further studies for Oxycodone ER, that the FDA will approve any of the Company's requested abuse-deterrent label claims or that the FDA will ultimately approve the NDA for the sale of Oxycodone ER in the U.S. market, or that it will ever be successfully commercialized.